Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells
Cisplatin is a known antitumor drug, but its mechanisms of action are not fully elucidated. In this research, we studied the anticancer potential of cisplatin at doses of 1, 2, or 3 μM using HL-60 cells as a test model. We investigated cisplatin effects at the molecular level using RNA sequencing, c...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-01-01
|
| Series: | Biomarker Insights |
| Online Access: | https://doi.org/10.4137/BMI.S39445 |
| _version_ | 1818149133343522816 |
|---|---|
| author | Venkatramreddy Velma Shaloam R. Dasari Paul B. Tchounwou |
| author_facet | Venkatramreddy Velma Shaloam R. Dasari Paul B. Tchounwou |
| author_sort | Venkatramreddy Velma |
| collection | DOAJ |
| description | Cisplatin is a known antitumor drug, but its mechanisms of action are not fully elucidated. In this research, we studied the anticancer potential of cisplatin at doses of 1, 2, or 3 μM using HL-60 cells as a test model. We investigated cisplatin effects at the molecular level using RNA sequencing, cell cycle analysis, and apoptotic assay after 24, 48, 72, and 96 hours of treatment. The results show that many genes responsible for molecular and cellular functions were significantly altered. Cisplatin treatment also caused the cells to be arrested at the DNA synthesis phase, and as the time increases, the cells gradually accumulated at the sub-G1 phase. Also, as the dose increases, a significant number of cells entered into the apoptotic and necrotic stages. Altogether, the data show that low doses of cisplatin significantly impact the viability of HL-60 cells, through modulation of gene expression, cell cycle, and apoptosis. |
| first_indexed | 2024-12-11T13:02:11Z |
| format | Article |
| id | doaj.art-ab52296214ab4cbbb74bfe62902246ef |
| institution | Directory Open Access Journal |
| issn | 1177-2719 |
| language | English |
| last_indexed | 2024-12-11T13:02:11Z |
| publishDate | 2016-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Biomarker Insights |
| spelling | doaj.art-ab52296214ab4cbbb74bfe62902246ef2022-12-22T01:06:26ZengSAGE PublishingBiomarker Insights1177-27192016-01-011110.4137/BMI.S39445Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia CellsVenkatramreddy Velma0Shaloam R. Dasari1Paul B. Tchounwou2Cellomics and Toxicogenomics Research Laboratory, NIH/NIMHD RCMI-Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, Jackson, MS, USA.Cellomics and Toxicogenomics Research Laboratory, NIH/NIMHD RCMI-Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, Jackson, MS, USA.Cellomics and Toxicogenomics Research Laboratory, NIH/NIMHD RCMI-Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, Jackson, MS, USA.Cisplatin is a known antitumor drug, but its mechanisms of action are not fully elucidated. In this research, we studied the anticancer potential of cisplatin at doses of 1, 2, or 3 μM using HL-60 cells as a test model. We investigated cisplatin effects at the molecular level using RNA sequencing, cell cycle analysis, and apoptotic assay after 24, 48, 72, and 96 hours of treatment. The results show that many genes responsible for molecular and cellular functions were significantly altered. Cisplatin treatment also caused the cells to be arrested at the DNA synthesis phase, and as the time increases, the cells gradually accumulated at the sub-G1 phase. Also, as the dose increases, a significant number of cells entered into the apoptotic and necrotic stages. Altogether, the data show that low doses of cisplatin significantly impact the viability of HL-60 cells, through modulation of gene expression, cell cycle, and apoptosis.https://doi.org/10.4137/BMI.S39445 |
| spellingShingle | Venkatramreddy Velma Shaloam R. Dasari Paul B. Tchounwou Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells Biomarker Insights |
| title | Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells |
| title_full | Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells |
| title_fullStr | Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells |
| title_full_unstemmed | Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells |
| title_short | Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells |
| title_sort | low doses of cisplatin induce gene alterations cell cycle arrest and apoptosis in human promyelocytic leukemia cells |
| url | https://doi.org/10.4137/BMI.S39445 |
| work_keys_str_mv | AT venkatramreddyvelma lowdosesofcisplatininducegenealterationscellcyclearrestandapoptosisinhumanpromyelocyticleukemiacells AT shaloamrdasari lowdosesofcisplatininducegenealterationscellcyclearrestandapoptosisinhumanpromyelocyticleukemiacells AT paulbtchounwou lowdosesofcisplatininducegenealterationscellcyclearrestandapoptosisinhumanpromyelocyticleukemiacells |